Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2003
12/18/2003US20030232839 Administering heterocyclic amines, as controllers of central nervous system(CNS) such as serotonin receptors
12/18/2003US20030232837 17-Beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
12/18/2003US20030232834 Administering mixtures of apical sodium co-dependent bile acid transport inhibitors and 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, as antilipemic agents
12/18/2003US20030232805 Administering a dual serotonin/norepinephrine reuptake inhibitor or a triple monoamine reuptake inhibitor for serotonin/noradrenaline/ dopamine
12/18/2003US20030232796 Nanoparticulate polycosanol formulations & novel polycosanol combinations
12/18/2003US20030232795 Administering selective estrogen receptor modulators that possesses tissue-specific ER agonist activity
12/18/2003US20030232767 Activating cancerous cells response to therapeutic agents, by administering cisplatin or oxaliplatin, applying ionizing radiation and hydrogen peroxide
12/18/2003US20030232765 Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
12/18/2003US20030232753 Combined tissue factor methods for coagulation and tumor treatment
12/18/2003US20030232752 Proliferated cell lines and uses thereof
12/18/2003US20030232741 Methods of treatment of glaucoma and other conditions mediated by NOS-2 expression via inhibition of the EGFR pathway
12/18/2003US20030232739 Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
12/18/2003US20030232738 Increasing JAK3 (Janus kinase) action in CD4+ T lymphocytes of the patient infected with human immunodeficiency virus (HIV), wherein such CD4+ T lymphocytes express CD4 that has been ligated by gp120 on human immunodeficiency virus
12/18/2003US20030232349 Nucleic acid and amino acid sequences of proteases and the use of these sequences in the diagnosis and treatment of gastrointestinal, cardiovascular, autoimmune/inflammatory, cell proliferative, and neurological disorders
12/18/2003US20030232334 Novel compositions and methods for cancer
12/18/2003US20030232100 Compositions for treatment of diseases arising from secretion of mast cell biochemicals
12/18/2003US20030232093 Stable bicarbonate-based solution in a single container
12/18/2003US20030232091 Particles or microspheres of a hydrophobic matrix material having retinol encapsulated therein; sustained release of retinol during the product shelf-life
12/18/2003US20030232090 Anhydrous antifungal gel comprising polyhydric alcohol(s), a gelling agent and an antifungal azole such as econazole; treating oral and vaginal fungal and bacterial infections
12/18/2003US20030232078 Formulation & dosage form for the controlled delivery of therapeutic agents
12/18/2003US20030232077 Rapidly disintegrating tablet
12/18/2003US20030232074 For stimulating immune activation; for screening immunostimulatory compounds
12/18/2003US20030232073 Enhanced drug delivery in transdermal systems
12/18/2003US20030232063 Aminosulfonic acid compounds for promoting desquamation of the skin
12/18/2003US20030232057 Method and composition for inducing tolerance to an antigenic material
12/18/2003US20030232049 Multispecific reagent for selectively stimulating cell surface receptors
12/18/2003US20030232024 For therapy of hyperpigmentation and vitiligo
12/18/2003CA2590618A1 Method of treating cancer using kinase inhibitors
12/18/2003CA2493890A1 Methods for using adamts-12, an integrin and metalloprotease with thrombospondin motifs
12/18/2003CA2489083A1 Method for identifying agonists or antagonists for the g-protein coupled mas-like 1 receptor
12/18/2003CA2488883A1 Method for identifying agonists or antagonists for the gpr45-like/gpr63 receptor
12/18/2003CA2488803A1 Use of ramoplanin to treat diseases associated with the use of antibiotics
12/18/2003CA2488798A1 Substituted pyrrolines as kinase inhibitors
12/18/2003CA2488719A1 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
12/18/2003CA2488617A1 Nanoparticulate sterol formulations and sterol combinations
12/18/2003CA2488498A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
12/18/2003CA2488385A1 Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
12/18/2003CA2488108A1 Liquid formulation of decitabine and use of the same
12/18/2003CA2487983A1 Method of treating cancer using kinase inhibitors
12/18/2003CA2487977A1 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
12/18/2003CA2487899A1 Overactive bladder treating drug
12/18/2003CA2487414A1 Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
12/18/2003CA2487413A1 Methods of treating angiogenesis, tumor growth, and metastasis
12/18/2003CA2487147A1 Combinations comprising epothilones and pharmaceutical uses thereof
12/18/2003CA2486584A1 Compositions and methods for treating diabetes
12/18/2003CA2486270A1 Vegfr modulating agents and methods for liver growth and liver protection
12/18/2003CA2485709A1 Novel screens to identify agents that modulate retinal blood vessel function and pericyte function and diagnostic and therapeutic application therefor
12/18/2003CA2484514A1 Compositions and methods for the prophylaxis and treatment of aphthous ulcers and herpes simplex lesions
12/18/2003CA2461444A1 Antithrombogenic platiniferous ceramic composition and article containing the same
12/17/2003EP1371730A2 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus
12/17/2003EP1371660A1 Vaccine
12/17/2003EP1371376A1 Antipruritics
12/17/2003EP1371367A1 Use of naaladase inhibitors for the manufacture of a medicament for the treatment of certain diseases
12/17/2003EP1370684A2 Polynucleotides related to colon cancer
12/17/2003EP1370662A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
12/17/2003EP1370655A2 Secreted human proteins
12/17/2003EP1370586A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370585A2 Nucleic acids of the human abcc12 gene, vectors containing such nucleic acids and uses thereof
12/17/2003EP1370584A2 Nuclear hormone receptor ligand binding domain
12/17/2003EP1370583A1 Polypeptides and nucleic acids for bolekine
12/17/2003EP1370580A2 A new essential downstream component of the wingless signalling pathway
12/17/2003EP1370572A2 Mitochondrial membrane permeabilization by hiv-1 vpr and methods of screening
12/17/2003EP1370558A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists
12/17/2003EP1370551A2 New compounds useful as antibacterial agents
12/17/2003EP1370548A1 P-thienylbenzyl-amides serving as agonists of angiotensin-(1-7)-receptors, method for the production thereof, their use and pharmaceutical preparations containing the same
12/17/2003EP1370539A1 Hiv inhibiting n-aminoimidazole derivatives
12/17/2003EP1370528A1 Mch antagonists and their use in the treatment of obesity
12/17/2003EP1370520A1 Aryl and biaryl compounds having mch modulatory activity
12/17/2003EP1370510A2 Hiv integrase inhibitors
12/17/2003EP1370302A1 Dry powder compositions comprising labelled particles for inhalation
12/17/2003EP1370294A2 Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
12/17/2003EP1370293A2 Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
12/17/2003EP1370292A1 Use of cd23 antagonists for the treatment of neoplastic disorders
12/17/2003EP1370277A1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis
12/17/2003EP1370275A2 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
12/17/2003EP1370270A2 Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
12/17/2003EP1370268A2 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
12/17/2003EP1370267A2 Use of propentofylline to control intraocular pressure
12/17/2003EP1370266A1 Method of treatment
12/17/2003EP1370264A2 Nicotinic receptor agonists for the treatment of inflammatory diseases
12/17/2003EP1370261A2 New use
12/17/2003EP1370259A1 Use of melatonin in the manufacture of a medicament for treating attention deficit hyperactive disorder
12/17/2003EP1370249A1 Novel dendriticpolymers and their biomedical uses
12/17/2003EP1370246A2 Modulation of release from dry powder formulations
12/17/2003EP1370243A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
12/17/2003EP1370242A1 Method to obtain microparticles containing a h+, k+ -atp-ase inhibitor
12/17/2003EP1370237A2 Presbyopia treatment by lens alteration
12/17/2003EP1370211A2 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
12/17/2003EP1370206A1 Devices for local and systemic delivery of active substances and methods of manufacturing thereof
12/17/2003EP1370144A1 Noninvasive measurements of chemical substances
12/17/2003EP1263425B1 Use of comt inhibitors as analgesics
12/17/2003EP1162970B1 Anti-inflammatory uses of manzamines
12/17/2003EP1109805B1 Inhibitors of bacterial nad synthetase
12/17/2003EP1066043B1 Materials for the treatment of conditions involving mast cells, basophils and eosinophils
12/17/2003EP1028715B1 Dosage composition for nasal delivery comprising vibrio cholera zonula occludens toxin as absorption enhancer
12/17/2003EP1001752B1 Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
12/17/2003EP0641218B1 Use of angiotensin antagonist (at1) for reducing post myocardial infarct mobidity and mortality
12/17/2003CN1462193A Oral preparations
12/17/2003CN1462192A Blood cell production via activation of hemeglobin scavenger receptor
12/17/2003CN1462191A Treatment of ocute coronary syndrome with GLP-1
1 ... 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 ... 1151